Lig­and Phar­ma part­ner wins Chi­nese ap­proval for an­ti-PD-1; Brick­ell re­ceives ex­clu­sive rights to DYRK1A in­hibitor

Cal­i­for­nia bio­phar­ma com­pa­ny Lig­and Phar­ma­ceu­ti­cals an­nounced to­day that part­ner Glo­ria Bio­sciences has re­ceived a new ap­proval from Chi­na’s Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion.

This ap­proval is for the an­ti-PD-1 an­ti­body zim­bere­limab for treat­ing re­cur­rent or re­frac­to­ry clas­si­cal Hodgkin’s lym­phoma. Glo­ria Bio has de­vel­op­ment and com­mer­cial­iza­tion rights in Chi­na for zim­bere­limab through a sub­li­cense agree­ment with Wuxi Bi­o­log­ics Ire­land, Lig­and’s li­censee.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER